Clinical trial
Safety and Efficacy Study of Small Interfering RNA Molecule (Cand5) to Treat…
NCT00306904 · OPKO Health, Inc., Industry · Completed
Key facts
| NCT number | NCT00306904 |
|---|---|
| Title | Safety and Efficacy Study of Small Interfering RNA Molecule (Cand5) to Treat Diabetic Macular Edema |
| Official title | A Phase II, Pharmacokinetic, Randomized, Double-Masked, Controlled, Dose Comparison Study of Cand5 for Intravitreal Injection for the Treatment of Diabetic Macular Edema |
| Lead sponsor | OPKO Health, Inc., Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Diabetic Macular Edema |
| Intervention type | Drug |
| Interventions | bevasiranib |
| Enrollment | 48 |
| Start date | Jan 1, 2006 |
| Primary completion | Sep 1, 2007 |
| Completion | Dec 1, 2007 |
| First posted | Mar 27, 2006 |
| Last update posted | Jul 25, 2008 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: